{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:45:13Z","timestamp":1792320313184,"version":"4.4.0"},"reference-count":348,"publisher":"Impact Journals, LLC","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,7,15]]},"DOI":"10.18632\/oncotarget.2209","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T19:39:30Z","timestamp":1442345970000},"page":"4603-4650","source":"Crossref","is-referenced-by-count":223,"title":["Deregulation of the EGFR\/PI3K\/PTEN\/Akt\/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention"],"prefix":"10.18632","volume":"5","author":[{"given":"Nicole M.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Sokolosky","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Stadelman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Libra","sequence":"additional","affiliation":[{"name":"Department of Bio-Medical Sciences, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Candido","sequence":"additional","affiliation":[{"name":"Department of Bio-Medical Sciences, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[{"name":"Department of Bio-Medical Sciences, University of Catania, Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Polesel","sequence":"additional","affiliation":[{"name":"Unit of Epidemiology and Biostatistics, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Maestro","sequence":"additional","affiliation":[{"name":"Experimental Oncology 1, CRO IRCCS, National Cancer Institute, Aviano, Pordenone, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"D\u2019Assoro","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmyla","family":"Drobot","sequence":"additional","affiliation":[{"name":"Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Rakus","sequence":"additional","affiliation":[{"name":"Department of Animal Molecular Physiology, Institute of Experimental Biology, Wroclaw University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Gizak","sequence":"additional","affiliation":[{"name":"Department of Animal Molecular Physiology, Institute of Experimental Biology, Wroclaw University, Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Laidler","sequence":"additional","affiliation":[{"name":"Chair of Medical Biochemistry, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Duli\u0144ska-Litewka","sequence":"additional","affiliation":[{"name":"Chair of Medical Biochemistry, Jagiellonian University Medical College, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Basecke","sequence":"additional","affiliation":[{"name":"Department of Medicine University of G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mijatovic","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute for Biological Research \u201cSinisa Stankovic\u201d University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijela","family":"Maksimovic-Ivanic","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute for Biological Research \u201cSinisa Stankovic\u201d University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Montalto","sequence":"additional","affiliation":[{"name":"Biomedical Department of Internal Medicine and Specialties, University of Palermo, Palermo, Italy"},{"name":"Consiglio Nazionale delle Ricerche,Istituto di Biomedicina e Immunologia Molecolare \u201cAlberto Monroy\u201d, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchiorre","family":"Cervello","sequence":"additional","affiliation":[{"name":"Consiglio Nazionale delle Ricerche,Istituto di Biomedicina e Immunologia Molecolare \u201cAlberto Monroy\u201d, Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy L.","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya N.","family":"Demidenko","sequence":"additional","affiliation":[{"name":"Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Martelli","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche e Neuromotorie, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Cocco","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche e Neuromotorie, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Steelman","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"McCubrey","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University Greenville, NC 27858 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,7,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Jemal","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/1055-9965.20.14.1","article-title":"Epidemiology of male breast cancer","volume":"14","author":"Swede","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/1471-2407-12-510","article-title":"Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas","volume":"12","author":"Fox","year":"2012","journal-title":"BMC Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","article-title":"A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1","volume":"266","author":"Fry","year":"1994","journal-title":"Science"},{"key":"5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/513891","article-title":"Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13","volume":"61","author":"Goldgar","year":"1997","journal-title":"Am J Hum Genet"},{"key":"6","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Phillips","year":"2004","journal-title":"Cancer Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.971","article-title":"Evaluating HER2 amplification and overexpression in breast cancer","volume":"195","author":"Cooke","year":"2001","journal-title":"J Pathol"},{"key":"8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"key":"10","doi-asserted-by":"crossref","first-page":"461","DOI":"10.18632\/aging.100334","article-title":"BRCA1 A-complex fine tunes repair functions of BRCA1","volume":"3","author":"Khanna","year":"2011","journal-title":"Aging"},{"key":"11","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4161\/cc.22776","article-title":"BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.18632\/oncotarget.462","article-title":"CA1\/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells","volume":"3","author":"Elshamy","year":"2012","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.18632\/oncotarget.433","article-title":"Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1","volume":"3","author":"Sharan","year":"2012","journal-title":"Oncotarget"},{"key":"14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.18632\/oncotarget.285","article-title":"Elevated PI3K signaling drives multiple breast cancer subtypes","volume":"2","author":"Egan","year":"2011","journal-title":"Oncotarget"},{"key":"15","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.4161\/cc.22215","article-title":"DNA2 and EXO1 in replication-coupled, homology-directed repair and in the interplay between HDR and the FA\/BRCA network","volume":"11","author":"Campbell","year":"2012","journal-title":"Cell Cycle"},{"key":"16","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.4161\/cc.21396","article-title":"Analysis of centrosome localization of BRCA1 and its activity in suppressing centrosomal aster formation","volume":"11","author":"Fukasawa","year":"2012","journal-title":"Cell Cycle"},{"key":"17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4161\/cc.10.3.14738","article-title":"BRCA1, microRNAs and cancer predisposition: challenging the dogma","volume":"10","author":"Calin","year":"2011","journal-title":"Cell Cycle"},{"key":"18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/cc.10.1.14359","article-title":"Rare BRCA1 haplotypes including 3\u2019UTR SNPs associated with breast cancer risk","volume":"10","author":"Weidhaas","year":"2011","journal-title":"Cell Cycle"},{"key":"19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Tainsky","year":"1990","journal-title":"Science"},{"key":"20","first-page":"5291","article-title":"p53 mutations in breast cancer","volume":"52","author":"Prosser","year":"1992","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"e19249","DOI":"10.1371\/journal.pone.0019249","article-title":"Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel","volume":"6","author":"L\u00f8nning","year":"2011","journal-title":"PLoS One"},{"key":"22","first-page":"279","article-title":"Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells","volume":"8","author":"Lee","year":"1993","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.269","article-title":"Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors","volume":"2","author":"Mohammad","year":"2011","journal-title":"Oncotarget"},{"key":"24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.18632\/oncotarget.243","article-title":"MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk","volume":"2","author":"Lonning","year":"2011","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.4161\/cc.11.5.19492","article-title":"The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells","volume":"11","author":"Yaswen","year":"2012","journal-title":"Cell Cycle"},{"key":"26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4161\/cc.10.10.15703","article-title":"RB1 and p53 at the crossroad of EMT and triple-negative breast cancer","volume":"10","author":"Zacksenhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"27","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","article-title":"Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs","volume":"10","author":"D\u2019Orazi","year":"2011","journal-title":"Cell Cycle"},{"key":"28","first-page":"345","article-title":"The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair","volume":"15","author":"Parvin","year":"2013","journal-title":"Current Opin Cell Biol"},{"issue":"8","key":"29","first-page":"927","article-title":"\u201cBASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures\u201d","volume":"14","author":"Qin","journal-title":"Genes Dev"},{"key":"30","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1349-7006.2004.tb02195.x","article-title":"Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage","volume":"95","author":"Miki","year":"2004","journal-title":"Cancer Sci"},{"key":"31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","article-title":"Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2\u201d","volume":"22","author":"Livingston","year":"2006","journal-title":"Mol. Cell"},{"key":"32","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2013.2541","article-title":"Hereditary breast and ovarian cancer susceptibility genes","volume":"30","author":"Matsuura","year":"2013","journal-title":"Oncol Rep"},{"key":"33","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1200\/JCO.2011.35.2682","article-title":"Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience","volume":"29","author":"Albarracin","year":"2011","journal-title":"J Clin Oncol"},{"key":"34","first-page":"3093","article-title":"Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers","volume":"117","author":"Tung","year":"2012","journal-title":"Cancer"},{"key":"35","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Meric-Bernstam","year":"2011","journal-title":"Clin Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-010-0859-2","article-title":"Effect of BRCA1\/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis","volume":"122","author":"Lee","year":"2010","journal-title":"Breast Cancer Res & Treat"},{"key":"37","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2407-10-90","article-title":"Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer","volume":"10","author":"Federico","year":"2010","journal-title":"BMC Cancer"},{"key":"38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ijc.26369","article-title":"Hereditary Breast Cancer Clinical Study Group. The risk of breast cancer in women with a BRCA1 mutation from North America and Poland","volume":"131","author":"Eisen","year":"2012","journal-title":"Int J Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.18632\/aging.100325","article-title":"Mutations in the BRCT binding site of BRCA1 result in hyper-recombination","volume":"3","author":"Valerie","year":"2011","journal-title":"Aging"},{"key":"40","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4161\/cc.11.4.19212","article-title":"BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies","volume":"11","author":"Valerie","year":"2012","journal-title":"Cell Cycle"},{"key":"41","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.4161\/cc.22316","article-title":"Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1, autophagy and ketone body production","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.18632\/aging.100316","article-title":"Gerosuppressant metformin: less is more","volume":"3","author":"Vazquez-Martin","year":"2011","journal-title":"Aging"},{"key":"43","article-title":"Molecular pathways: Preclinical models and clinical trials with metformin in breast cancer","volume":"2014","author":"Thompson","journal-title":"Clin Cancer Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4161\/cc.10.9.15479","article-title":"Protein phosphatase PP6 is required for homology-directed repair of DNA double-strand breaks","volume":"10","author":"Xu","year":"2011","journal-title":"Cell Cycle"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Bonotto, Gerratana, Poletto, Driol, Giangreco, Russo, Minisini, Andreetta, Mansutti, Pisa, Fasola, Puglisi. Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario. Oncologist. 2014. In Press.","DOI":"10.1634\/theoncologist.2014-0002"},{"key":"46","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Broaddus","year":"2010","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1289\/ehp.1002864","article-title":"Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations","volume":"119","author":"Makris","year":"2011","journal-title":"Envir Health Pers"},{"key":"48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/GRF.0b013e3182080056","article-title":"Breast cancer: epidemiology and risk factors","volume":"54","author":"Stuckey","year":"2011","journal-title":"Clin Obst & Gyn"},{"key":"49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-072X-10-32","article-title":"Estrogen receptor positive breast cancers and their association with environmental factors","volume":"10","author":"Derryberry","year":"2011","journal-title":"Int J Health Geograp"},{"key":"50","unstructured":"Schmidt. IOM issues report on breast cancer and the environment. Environmental Health Perspectives. 2012; 307. 120:p. 348. Hampton. Breast cancer symposium highlights risk, recurrence, and research trials. JAMA. 2012; ppp. a60\u2013350. \u20131."},{"key":"51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-pharmtox-010611-134659","article-title":"Perinatal environmental exposures affect mammary development, function, and cancer risk in adulthood","volume":"52","author":"Newbold","year":"2012","journal-title":"Ann Rev Pharm & Tox"},{"key":"52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/09603123.2011.588321","article-title":"Ambient air pollution is associated with the increased incidence of breast cancer in US","volume":"22","author":"Bina","year":"2012","journal-title":"Int J Envir Health Res"},{"key":"53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10549-012-2257-4","article-title":"Exposure to polychlorinated biphenyl (PCB) congeners measured shortly after giving birth and subsequent risk of maternal breast cancer before age 50","volume":"136","author":"Cirillo","year":"2012","journal-title":"Breast Cancer Res & Treat"},{"key":"54","first-page":"120","article-title":"Increased cancer burden among pesticide applicators and others due to pesticide exposure","volume":"63","author":"Bonner","year":"2013","journal-title":"[Review] CA: a Cancer Journal for Clinicians"},{"key":"55","first-page":"290","article-title":"Role of melatonin on electromagnetic radiation-induced oxidative stress and Ca2+ signaling molecular pathways in breast cancer","volume":"32","author":"Demirci","year":"2012","journal-title":"J Rec & Signal Trans Res"},{"key":"56","first-page":"189","article-title":"The role of cadmium and nickel in estrogen receptor signaling and breast cancer: metalloestrogens or not?","volume":"30","author":"Louie","year":"2012","journal-title":"J Envir Science & Health Part C Envir Carcino & Ecotox Rev"},{"key":"57","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/ijerph9051846","article-title":"Breast cancer risk, fungicide exposure and CYP1A1*2A gene-environment interactions in a province-wide case control study in Prince Edward Island, Canada","volume":"9","author":"Guernsey","year":"2012","journal-title":"Int J Envir Res & Public Health"},{"key":"58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1476-069X-11-28","article-title":"Complex organochlorine pesticide mixtures as determinant factor for breast cancer risk: a population-based case-control study in the Canary Islands (Spain)","volume":"11","author":"Luzardo","year":"2012","journal-title":"Envir Health: A Global Access Sci Source"},{"key":"59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1001\/archinternmed.2012.2329","article-title":"Environmental causes of breast cancer and radiation from medical imaging: findings from the Institute of Medicine report","volume":"172","author":"Smith-Bindman","year":"2012","journal-title":"Arc Intern Med"},{"key":"60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/ijc.26460","article-title":"Million Women Study Collaborators. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer","volume":"131","author":"Beral","year":"2012","journal-title":"Int JCancer"},{"key":"61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.tox.2012.03.004","article-title":"Pre-diagnostic acrylamide exposure and survival after breast cancer among postmenopausal Danish women","volume":"296","author":"Halkj\u00e6r","year":"2012","journal-title":"Toxicology"},{"key":"62","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1158\/0008-5472.CAN-12-4313","article-title":"TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness","volume":"73","author":"Marincola","year":"2013","journal-title":"Cancer Res"},{"issue":"3","key":"63","doi-asserted-by":"crossref","first-page":"e58182","DOI":"10.1371\/journal.pone.0058182","article-title":"Prevalence of BRCA1 mutations in familial and sporadic Greek ovarian cancer cases","volume":"8","author":"Makatsoris","year":"2013","journal-title":"PLoS One"},{"key":"64","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2013.2541","article-title":"Hereditary breast and ovarian cancer susceptibility genes","volume":"30","author":"Matsuura","year":"2013","journal-title":"Oncol Rep"},{"key":"65","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/sj.onc.1202509","article-title":"Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics","volume":"18","author":"Solomon","year":"1999","journal-title":"Oncogene"},{"key":"66","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.2741\/4185","article-title":"Breast cancer genes: beyond BRCA1 and BRCA2","volume":"18","author":"Vega","year":"2013","journal-title":"Front Biosci"},{"key":"67","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00432-010-0824-9","article-title":"Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer","volume":"136","author":"Georgieva","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"68","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/bcr435","article-title":"Mutation analysis of the CHK2 gene in breast carcinoma and other cancers","volume":"4","author":"Bergthorsson","year":"2002","journal-title":"Breast Cancer Res"},{"key":"69","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1007\/s13277-013-0983-9","article-title":"MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency","volume":"34","author":"Wei","year":"2013","journal-title":"Tumour Biol"},{"key":"70","first-page":"5291","article-title":"p53 mutations in breast cancer","volume":"52","author":"Prosser","year":"1992","journal-title":"Cancer Res"},{"key":"71","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12032-011-9875-2","article-title":"The TP53 gene polymorphisms and survival of sporadic breast cancer patients","volume":"29","author":"Rudan","year":"2012","journal-title":"Med Oncol"},{"key":"72","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10549-008-0192-1","article-title":"Silencing of estrogen receptor alpha (ERalpha) gene by promoter hypermethylation is a frequent event in Chinese women with sporadic breast cancer","volume":"117","author":"Wei","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"73","first-page":"102","article-title":"Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer","volume":"14","author":"Akbari","year":"2012","journal-title":"Cell J"},{"key":"74","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s12032-011-0107-6","article-title":"Clinical implications of ER\u03b2 methylation on sporadic breast cancers in Chinese women","volume":"29","author":"Jin","year":"2012","journal-title":"Med Oncol"},{"key":"75","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Bartlett","year":"2003","journal-title":"J Pathol"},{"key":"76","doi-asserted-by":"crossref","first-page":"R246","DOI":"10.1186\/bcr783","article-title":"Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling","volume":"6","author":"Cooke","year":"2004","journal-title":"Breast Cancer Res"},{"key":"77","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/bjc.1998.689","article-title":"Expression of c-erbB3 protein in primary breast carcinomas","volume":"78","author":"Kutty","year":"1998","journal-title":"Br J Cancer"},{"key":"78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1003","article-title":"EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival","volume":"196","author":"Nesland","year":"2002","journal-title":"J Pathol"},{"key":"79","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s004280000392","article-title":"Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas","volume":"439","author":"Nesland","year":"2001","journal-title":"Virchows Arch"},{"key":"80","first-page":"4217","article-title":"Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay","volume":"6","author":"Peyrat","year":"2000","journal-title":"Clin Cancer Res"},{"key":"81","first-page":"1455","article-title":"mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen","volume":"23","author":"Peyrat","year":"2003","journal-title":"Anticancer Res"},{"key":"82","doi-asserted-by":"crossref","first-page":"e26760","DOI":"10.1371\/journal.pone.0026760","article-title":"Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib","volume":"6","author":"Duyster","year":"2011","journal-title":"PLoS One"},{"key":"83","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1158\/1078-0432.CCR-13-1038","article-title":"Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2","volume":"19","author":"Arteaga","year":"2013","journal-title":"Clin Cancer Res"},{"key":"84","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1158\/0008-5472.CAN-13-0687","article-title":"Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications","volume":"73","author":"Arteaga","year":"2013","journal-title":"Cancer Res"},{"key":"85","first-page":"973584","article-title":"Clinical significance of HER-2 splice variants in breast cancer progression and drug resistance","volume":"2013","author":"Tyson-Capper","year":"2013","journal-title":"Int J Cell Biol"},{"key":"86","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/annonc\/mdl322","article-title":"EGFR mutations in exons 18-21 in sporadic breast cancer","volume":"18","author":"Harris","year":"2007","journal-title":"Ann Oncol"},{"key":"87","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/bcr2857","article-title":"Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy","volume":"13","author":"Tan","year":"2011","journal-title":"Breast Cancer Res"},{"key":"88","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/modpathol.3800438","article-title":", EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations","volume":"18","author":"Chen","year":"2005","journal-title":"Mod Pathol"},{"key":"89","doi-asserted-by":"crossref","first-page":"R1028","DOI":"10.1186\/bcr1341","article-title":"Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis","volume":"7","author":"Schmitt","year":"2005","journal-title":"Breast Cancer Res"},{"key":"90","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.2004","article-title":"EGFR amplification and lack of activating mutations in metaplastic breast carcinomas","volume":"209","author":"Ashworth","year":"2006","journal-title":"J Pathol"},{"key":"91","first-page":"3081","article-title":"Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer","volume":"60","author":"Lippman","year":"2000","journal-title":"Cancer Research"},{"key":"92","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ijc.10224","article-title":"Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis","volume":"98","author":"Tang","year":"2002","journal-title":"Int J Cancer"},{"key":"93","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/B:BREA.0000041585.26734.f9","article-title":"EGFR and EGFRvIII expression in primary breast cancer and cell lines","volume":"87","author":"Lippman","year":"2004","journal-title":"Breast Cancer Res & Treat"},{"key":"94","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.ejca.2006.03.033","article-title":"Molecular detection of EGFRvIII-positive cells in the peripheral blood of breast cancer patients","volume":"42","author":"Regateiro","year":"2006","journal-title":"Eur J Cancer"},{"key":"95","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2006.09.8822","article-title":"Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer","volume":"25","author":"Nawaz","year":"2007","journal-title":"J Clin Oncol"},{"key":"96","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.24540","article-title":"EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer","volume":"125","author":"Tang","year":"2009","journal-title":"Int J Cancer"},{"key":"97","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2010-0302","article-title":"A review of an unfavorable subset of breast cancer: estrogen receptor positive progesterone receptor negative","volume":"16","author":"Mehta","year":"2011","journal-title":"Oncologist"},{"key":"98","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4161\/cbt.7.11.6847","article-title":"Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways","volume":"7","author":"Tang","year":"2008","journal-title":"Cancer Biol & Ther"},{"key":"99","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/ijc.24964","article-title":"EGFR variant-mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms","volume":"126","author":"Tang","year":"2010","journal-title":"Int J Cancer"},{"key":"100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2011.02.024","article-title":"CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells","volume":"306","author":"Tang","year":"2011","journal-title":"Cancer Letters"},{"issue":"6824","key":"101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Zlotnik","year":"2001","journal-title":"Nature"},{"key":"102","first-page":"46","article-title":"The role of chemokine receptor CXCR4 in breast cancer metastasis","volume":"3","author":"Zhao","year":"2013","journal-title":"Am J Cancer Res"},{"key":"103","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/0008-5472.CAN-11-2656","article-title":"Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma","volume":"72","author":"Wong","year":"2012","journal-title":"Cancer Research"},{"key":"104","doi-asserted-by":"crossref","first-page":"8933","DOI":"10.1073\/pnas.1537685100","article-title":"The ErbB2\/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation","volume":"100","author":"Hynes","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"105","article-title":"Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas","volume":"106","author":"Toyooka","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"106","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Gazdar","year":"2005","journal-title":"Cancer Res"},{"key":"107","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Ellis","year":"2013","journal-title":"Cancer Discov"},{"key":"108","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1586\/14737159.8.4.417","article-title":"EGFR\/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy","volume":"8","author":"Schmitt","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"key":"109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.bjc.6603910","article-title":"Targeting HER proteins in cancer therapy and the role of the non-target HER3","volume":"97","author":"Moasser","year":"2007","journal-title":"Br J Cancer"},{"key":"110","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1947601911431080","article-title":"ErbB2 Is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer","volume":"2","author":"Riese","year":"2011","journal-title":"Genes Cancer"},{"key":"111","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-4827(02)00100-3","article-title":"ErbB-4: mechanism of action and biology","volume":"284","author":"Carpenter","year":"2003","journal-title":"Exp Cell Res"},{"key":"112","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10911-008-9076-6","article-title":"HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer","volume":"13","author":"Jones","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"113","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10911-008-9079-3","article-title":"Role of ErbB4 in breast cancer","volume":"13","author":"Elenius","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"114","first-page":"393","article-title":"Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage","volume":"2","author":"Juhl","year":"2001","journal-title":"Int J Surg Investig"},{"key":"115","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/PDM.0b013e3180d0aab5","article-title":"Molecular differentiation of early and late stage laryngeal squamous cell carcinoma: an exploratory analysis","volume":"16","author":"Worsham","year":"2007","journal-title":"Diagn Mol Pathol"},{"key":"116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.yexmp.2007.12.002","article-title":"The status and role of ErbB receptors in human cancer","volume":"84","author":"Hajduch","year":"2008","journal-title":"Exp Mol Pathol"},{"key":"117","first-page":"2169","article-title":"Expression of erbB-4\/HER-4 growth factor receptor isoforms in ovarian cancer","volume":"61","author":"Langdon","year":"2001","journal-title":"Cancer Res"},{"key":"118","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2005.05.045","article-title":"Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix","volume":"99","author":"Gaffney","year":"2005","journal-title":"Gynecol Oncol"},{"key":"119","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3727\/000000006783981134","article-title":"Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines","volume":"16","author":"Riese","year":"2006","journal-title":"Oncol Res"},{"key":"120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-3835(02)00690-0","article-title":"A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines","volume":"192","author":"Riese","year":"2003","journal-title":"Cancer Lett"},{"key":"121","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.yexcr.2010.11.007","article-title":", II Ligand stimulation of ErbB4 and A constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines","volume":"317","author":"Riese","year":"2011","journal-title":"Exp Cell Res"},{"key":"122","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/sj.onc.1209794","article-title":"A constitutively active ERBB4\/HER4 allele with enhanced transcriptional coactivation and cell-killing activities","volume":"26","author":"Jones","year":"2007","journal-title":"Oncogene"},{"key":"123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08977190802312844","article-title":"EGFR family: structure physiology signalling and therapeutic targets","volume":"26","author":"Burgess","year":"2008","journal-title":"Growth Factors"},{"key":"124","first-page":"3932","article-title":"Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma","volume":"58","author":"Lunec","year":"1998","journal-title":"Cancer Res"},{"key":"125","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.bjc.6602184","article-title":"Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma","volume":"91","author":"Blamey","year":"2004","journal-title":"Br J Cancer"},{"key":"126","first-page":"5315","article-title":"Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo","volume":"59","author":"Lippman","year":"1999","journal-title":"Cancer Res"},{"key":"127","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1534\/genetics.112.142802","article-title":"Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver","volume":"192","author":"Schimenti","year":"2012","journal-title":"Genetics"},{"key":"128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jclinpath-2011-200569","article-title":"The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data","volume":"65","author":"Arenas","year":"2012","journal-title":"J Clin Pathol"},{"key":"129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccr.2013.08.004","article-title":"The RasGAP gene, RASAL2, is a tumor and metastasis suppressor","volume":"24","author":"Cichowski","year":"2013","journal-title":"Cancer Cell"},{"key":"130","first-page":"1149","article-title":"Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women","volume":"19","author":"Cao","year":"2008","journal-title":"Oncol Rep"},{"key":"131","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1158\/1541-7786.MCR-06-0263","article-title":"Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines","volume":"5","author":"Schutte","year":"2007","journal-title":"Mol Cancer Res"},{"key":"132","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-009-0460-8","article-title":"Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines","volume":"121","author":"Teunisse","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"133","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-04-0396","article-title":"Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis","volume":"64","author":"Der","year":"2004","journal-title":"Cancer Res"},{"key":"134","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1755-8794-3-26","article-title":"A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors","volume":"3","author":"Dai","year":"2010","journal-title":"BMC Med Genomics"},{"key":"135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10549-010-1073-y","article-title":"RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype","volume":"128","author":"Ellis","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"136","first-page":"2171","article-title":"RCP is a human breast cancer-promoting gene with Ras-activating function","volume":"119","author":"Lim","year":"2009","journal-title":"J Clin Invest"},{"key":"137","doi-asserted-by":"crossref","first-page":"10286","DOI":"10.1158\/0008-5472.CAN-07-1636","article-title":"Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways","volume":"67","author":"Dimri","year":"2007","journal-title":"Cancer Res"},{"key":"138","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/onc.2009.165","article-title":"BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases","volume":"28","author":"Green","year":"2009","journal-title":"Oncogene"},{"key":"139","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-3441","article-title":"Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics","volume":"69","author":"Monteagudo","year":"2009","journal-title":"Cancer Res"},{"key":"140","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1158\/0008-5472.CAN-07-6854","article-title":"An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer","volume":"68","author":"Hung","year":"2008","journal-title":"Cancer Res"},{"key":"141","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/bcr3113","article-title":"PIK3CA mutation impact on survival in breast cancer patients and in ER\u03b1, PR and ERBB2-based subgroups","volume":"14","author":"Bi\u00e8che","year":"2012","journal-title":"Breast Cancer Res"},{"key":"142","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/bjc.2013.164","article-title":"Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab","volume":"108","author":"Bieche","year":"2013","journal-title":"Br J Cancer"},{"key":"143","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/5042","article-title":"PIK3CA is implicated as an oncogene in ovarian cancer","volume":"21","author":"Gray","year":"1999","journal-title":"Nat Genet"},{"key":"144","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10549-009-0508-9","article-title":"PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis","volume":"122","author":"Green","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"145","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/onc.2010.257","article-title":"H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3","volume":"29","author":"Arteaga","year":"2010","journal-title":"Oncogene"},{"key":"146","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer","volume":"13","author":"Arteaga","year":"2011","journal-title":"Breast Cancer Res"},{"key":"147","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1158\/0008-5472.CAN-12-4579","article-title":"Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling","volume":"73","author":"Arteaga","year":"2013","journal-title":"Cancer Res"},{"key":"148","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Bernards","year":"2007","journal-title":"Cancer Cell"},{"key":"149","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1535-7163.MCT-10-1089","article-title":"PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer","volume":"10","author":"Meric-Bernstam","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"150","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/0008-5472.CAN-10-4026","article-title":"Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity","volume":"71","author":"Latif","year":"2011","journal-title":"Cancer Res"},{"key":"151","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1476-4598-7-83","article-title":"Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer","volume":"7","author":"Dahl","year":"2008","journal-title":"Mol Cancer"},{"key":"152","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2174\/138161212799859701","article-title":"Targeting the cancer initiating cell: the ultimate target for cancer therapy","volume":"18","author":"Bonati","year":"2012","journal-title":"Curr Pharm Des"},{"key":"153","first-page":"249","article-title":"Novel approaches to target cancer initiating cells-Eliminating the root of the cancer","volume":"52","author":"Steelman","year":"2012","journal-title":"Adv Enzyme Regul"},{"key":"154","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.18632\/oncotarget.802","article-title":"Advances in Targeting Signal Transduction Pathways","volume":"3","author":"Mazzarino","year":"2012","journal-title":"Oncotarget"},{"key":"155","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance","volume":"3","author":"Maksimovic-Ivanic","year":"2012","journal-title":"Oncotarget"},{"key":"156","doi-asserted-by":"crossref","first-page":"954","DOI":"10.18632\/oncotarget.652","article-title":"Mutations and deregulation of Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR cascades which alter therapy response","volume":"3","author":"Milella","year":"2012","journal-title":"Oncotarget"},{"key":"157","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/14728222.2012.694869","article-title":"Targeting the liver kinase B1\/AMP-dependent kinase pathway as a therapeutic strategy for hematological malignancies","volume":"16","author":"McCubrey","year":"2012","journal-title":"Exp Opin Thera Targets"},{"key":"158","doi-asserted-by":"crossref","first-page":"371","DOI":"10.18632\/oncotarget.477","article-title":"Dual inhibitors of phosphatidylinositol 3-kinase and mammalian target of rapamycin: A novel therapeutic strategy for acute leukemia treatment?","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"159","doi-asserted-by":"crossref","first-page":"811","DOI":"10.18632\/oncotarget.579","article-title":"Harnessing the PI3K\/Akt\/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jbior.2013.09.013","article-title":"Diverse roles of GSK-3: Tumor promoter-tumor suppressor, target in cancer therapy","volume":"54","author":"Steelman","year":"2014","journal-title":"Adv Biol Regul"},{"key":"161","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jbior.2013.11.003","article-title":"Nuclear PI-PLC\u03b21: An appraisal on targets and pathology","volume":"54","author":"Cocco","year":"2014","journal-title":"Adv Biol Regul"},{"key":"162","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/leu.2013.226","article-title":"Targeting the PI3K\/Akt\/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential","volume":"28","author":"Capitani","year":"2014","journal-title":"Leukemia"},{"key":"163","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.4161\/cc.25117","article-title":"Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients","volume":"12","author":"Chiarini","year":"2013","journal-title":"Cell Cycle"},{"key":"164","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/onc.2012.628","article-title":"The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha+ breast cancer cells","volume":"33","author":"Billadeau","year":"2014","journal-title":"Oncogene"},{"key":"165","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.18632\/oncotarget.762","article-title":"A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia","volume":"3","author":"Martelli","year":"2012","journal-title":"Oncotarget"},{"key":"166","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.4161\/cc.22852","article-title":"p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3","volume":"11","author":"McCubrey","year":"2012","journal-title":"Cell Cycle"},{"key":"167","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.4161\/cc.22786","article-title":"Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine","volume":"11","author":"McCubrey","year":"2012","journal-title":"Cell Cycle"},{"key":"168","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.18632\/oncotarget.691","article-title":"Effects of ectopic expression of NGAL on doxorubicin sensitivity","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"169","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jbior.2012.09.004","article-title":"Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment","volume":"53","author":"McCubrey","year":"2013","journal-title":"Adv Biol Regul"},{"key":"170","first-page":"2","article-title":"Nuclear phospholipase C \u03b21 signaling, epigenetics and treatments in MDS","volume":"52","author":"Cocco","year":"2013","journal-title":"Adv Biol Regul"},{"key":"171","first-page":"144","article-title":"Increased AKT signaling resulting from the loss of androgen responsiveness in prostate cancer","volume":"20","author":"Laidler","year":"2013","journal-title":"Curr Med Chem"},{"key":"172","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.4161\/cc.20859","article-title":"Activity of the selective I\u03baB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a","volume":"11","author":"Martelli","year":"2012","journal-title":"Cell Cycle"},{"key":"173","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/leu.2012.136","article-title":"Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia","volume":"26","author":"Martelli","year":"2012","journal-title":"Leukemia"},{"key":"174","first-page":"1858","article-title":"Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells","volume":"40","author":"D\u2019Assoro","year":"2012","journal-title":"Int J Oncol"},{"key":"175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2012.03.041","article-title":"Breast cancer, side population cells and ABCG2 expression","volume":"323","author":"Meeson","year":"2012","journal-title":"Cancer Lett"},{"key":"176","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/0008-5472.CAN-13-0260","article-title":"HER2 and breast cancer stem cells: more than meets the eye","volume":"73","author":"Wicha","year":"2013","journal-title":"Cancer Res"},{"key":"177","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1038\/onc.2008.207","article-title":"HER2 regulates the mammary stem\/progenitor cell population driving tumorigenesis and invasion","volume":"27","author":"Wicha","year":"2008","journal-title":"Oncogene"},{"key":"178","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1158\/0008-5472.CAN-12-3349","article-title":"HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab","volume":"73","author":"Clouthier","year":"2013","journal-title":"Cancer Res"},{"key":"179","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMc0801440","article-title":"HER2 status and benefit from adjuvant trastuzumab in breast cancer","volume":"358","author":"Wolmark","year":"2008","journal-title":"N Engl J Med"},{"key":"180","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-08-3087","article-title":"HER-2, notch, and breast cancer stem cells: targeting an axis of evil","volume":"15","author":"Wicha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"181","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00063030-200721050-00002","article-title":"Selective targeting of cancer stem cells: a new concept in cancer therapeutics","volume":"21","author":"Wicha","year":"2007","journal-title":"BioDrugs"},{"key":"182","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1158\/0008-5472.CAN-08-3441","article-title":"Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics","volume":"69","author":"Monteagudo","year":"2009","journal-title":"Cancer Res"},{"key":"183","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"184","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-012-2035-3","article-title":"Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers","volume":"134","author":"Bottai","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Gupta","year":"2009","journal-title":"Cancer Cell"},{"key":"186","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1210\/me.2010-0294","article-title":"SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells","volume":"25","author":"Chen","year":"2011","journal-title":"Mol Endocrinol"},{"key":"187","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-012-2081-x","article-title":"SGK3 is associated with estrogen receptor expression in breast cancer","volume":"134","author":"Liu","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"188","first-page":"281","article-title":"AKT-independent PI3-K signaling in cancer - emerging role for SGK3","volume":"5","author":"Sheppard","year":"2013","journal-title":"Cancer Manag Res"},{"key":"189","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.2009.26.1602","article-title":"Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer","volume":"28","author":"Swain","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"190","doi-asserted-by":"crossref","first-page":"e1000121","DOI":"10.1371\/journal.pbio.1000121","article-title":"Regulation of mammary stem\/progenitor cells by PTEN\/Akt\/beta-catenin signaling","volume":"7","author":"Wicha","year":"2009","journal-title":"PLoS Biol"},{"key":"191","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2012.48.5243","article-title":"Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy","volume":"31","author":"Arteaga","year":"2013","journal-title":"J Clin Oncol"},{"key":"192","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-12-3450","article-title":"Breast cancer stem cells: we\u2019ve got them surrounded","volume":"19","author":"Wicha","year":"2013","journal-title":"Clin Cancer Res"},{"key":"193","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2886","article-title":"NF-\u03baB, stem cells and breast cancer: the links get stronger","volume":"13","author":"Chariot","year":"2011","journal-title":"Breast Cancer Res"},{"key":"194","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/1078-0432.CCR-07-1046","article-title":"Down-regulation of phosphatidylinositol 3\u2019-kinase\/AKT\/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer","volume":"14","author":"Berruti","year":"2008","journal-title":"Clin Cancer Res"},{"key":"195","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2012.03.034","article-title":"Overcoming acquired resistance to letrozole by targeting the PI3K\/AKT\/mTOR pathway in breast cancer cell clones","volume":"323","author":"Petronini","year":"2012","journal-title":"Cancer Lett"},{"key":"196","doi-asserted-by":"crossref","first-page":"10208","DOI":"10.1073\/pnas.0907011107","article-title":"PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer","volume":"107","author":"Phillips","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"197","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr2594","article-title":"Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer","volume":"12","author":"Schiff","year":"2010","journal-title":"Breast Cancer Res"},{"key":"198","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1172\/JCI41680","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Arteaga","year":"2010","journal-title":"J Clin Invest"},{"key":"199","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1038\/onc.2008.49","article-title":"Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors","volume":"27","author":"McCubrey","year":"2008","journal-title":"Oncogene"},{"key":"200","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1158\/0008-5472.CAN-09-0042","article-title":"Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer","volume":"69","author":"Arteaga","year":"2009","journal-title":"Cancer Res"},{"key":"201","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1158\/1078-0432.CCR-08-1763","article-title":"Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer","volume":"15","author":"Hennessy","year":"2009","journal-title":"Clin Cancer Res"},{"key":"202","first-page":"1531","article-title":"Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review","volume":"11","author":"Kurzer","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"203","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.18632\/oncotarget.667","article-title":"Down-regulation of Sox7 is associated with aberrant activation of Wnt\/b-catenin signaling in endometrial cancer","volume":"3","author":"Ngan","year":"2012","journal-title":"Oncotarget"},{"key":"204","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.4161\/cc.21029","article-title":"Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation","volume":"11","author":"Ando","year":"2012","journal-title":"Cell Cycle"},{"key":"205","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.4161\/cc.20811","article-title":"Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis","volume":"11","author":"Wang","year":"2012","journal-title":"Cell Cycle"},{"key":"206","doi-asserted-by":"crossref","first-page":"212","DOI":"10.18632\/oncotarget.450","article-title":"A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers","volume":"3","author":"Halks-Miller","year":"2012","journal-title":"Oncotarget"},{"key":"207","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Coleman","year":"2012","journal-title":"Clin Cancer Res"},{"key":"208","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1158\/1078-0432.CCR-13-0615","article-title":"New strategies in endometrial cancer: Targeting the PI3K\/mTOR Pathway--The devil is in the details","volume":"19","author":"Myers","year":"2013","journal-title":"Clin Cancer Res"},{"key":"209","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1158\/1078-0432.CCR-12-3815","article-title":"PI3K pathway dependencies in endometrioid endometrial cancer cell lines. PI3K pathway dependencies in endometrioid endometrial cancer cell lines","volume":"19","author":"Downward","year":"2013","journal-title":"Clin Cancer Res"},{"key":"210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00428-010-0881-0","article-title":"PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer","volume":"456","author":"Schmitt","year":"2010","journal-title":"Virchows Arch"},{"key":"211","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","article-title":"High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability","volume":"1","author":"Broaddus","year":"2011","journal-title":"Cancer Discov"},{"key":"212","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/bcr3343","article-title":"Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer","volume":"14","author":"Gonzalez-Angulo","year":"2012","journal-title":"Breast Cancer Res"},{"key":"213","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.4161\/cc.10.17.17119","article-title":"Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells","volume":"10","author":"McCubrey","year":"2011","journal-title":"Cell Cycle"},{"key":"214","doi-asserted-by":"crossref","first-page":"7756","DOI":"10.1158\/0008-5472.CAN-06-4665","article-title":"The role of glycogen synthase kinase 3beta in the transformation of epidermal cells","volume":"67","author":"Luo","year":"2007","journal-title":"Cancer Res"},{"key":"215","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1158\/0008-5472.CAN-04-2501","article-title":"Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity","volume":"65","author":"Meric-Bernstam","year":"2005","journal-title":"Cancer Res"},{"key":"216","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.4161\/cc.7.18.6733","article-title":"GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma","volume":"7","author":"Dolcetti","year":"2008","journal-title":"Cell Cycle"},{"key":"217","doi-asserted-by":"crossref","first-page":"11462","DOI":"10.1158\/0008-5472.CAN-06-1969","article-title":"Adiponectin modulates the glycogen synthase kinase-3beta\/betacatenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice","volume":"66","author":"Xu","year":"2006","journal-title":"Cancer Res"},{"key":"218","doi-asserted-by":"crossref","first-page":"820","DOI":"10.4161\/cc.27728","article-title":"Inhibition of GSK-3\u03b2 activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells","volume":"13","author":"McCubrey","year":"2014","journal-title":"Cell Cycle"},{"key":"219","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1083\/jcb.200409067","article-title":"Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition","volume":"168","author":"Mercurio","year":"2005","journal-title":"J Cell Biol"},{"key":"220","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1471-2407-9-325","article-title":"Expression analysis of E-cadherin, slug and GSK3beta in invasive ductal carcinoma of breast","volume":"9","author":"Ralhan","year":"2009","journal-title":"BMC Cancer"},{"key":"221","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.4161\/cc.21573","article-title":"New light on p27(kip1) in breast cancer","volume":"11","author":"Baldassarre","year":"2012","journal-title":"Cell Cycle"},{"key":"222","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.4161\/cc.21194","article-title":"The role of S6K1 in ER-positive breast cancer","volume":"11","author":"Holz","year":"2012","journal-title":"Cell Cycle"},{"issue":"3","key":"223","doi-asserted-by":"crossref","first-page":"e4797","DOI":"10.1371\/journal.pone.0004797","article-title":"Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells","volume":"4","author":"Byers","year":"2009","journal-title":"PloS One"},{"key":"224","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.4161\/cc.10.23.18346","article-title":"TGF-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER+ breast cancer cells","volume":"10","author":"Raschella","year":"2011","journal-title":"Cell Cycle"},{"key":"225","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4161\/cc.11.3.19168","article-title":"Myb: getting involved in EMT","volume":"11","author":"Ramsay","year":"2012","journal-title":"Cell Cycle"},{"issue":"1","key":"226","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/cc.11.1.18733","article-title":"c-MYB and TGF: EMT\u2019s dynamic duo in breast cancer","volume":"11","author":"Sala","year":"2012","journal-title":"Cell Cycle"},{"key":"227","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.4161\/cc.10.12.15883","article-title":"Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas","volume":"10","author":"Herlyn","year":"2011","journal-title":"Cell Cycle"},{"key":"228","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-07-6094","article-title":"Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor","volume":"68","author":"Fuchs","year":"2008","journal-title":"Cancer Res"},{"key":"229","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/jpet.110.168930","article-title":"Estrogen receptor beta signaling through phosphatase and tensin homolog\/phosphoinositide 3-kinase\/Akt\/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein","volume":"334","author":"Bauer","year":"2010","journal-title":"J Pharmacology Exp Therapeutics"},{"key":"230","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/srep02474","article-title":"Ribophorin II regulates breast tumor initiation and metastasis through the functional suppression of GSK3beta","volume":"3","author":"Ochiya","year":"2013","journal-title":"Sci Rep"},{"key":"231","first-page":"91","article-title":"Billadeau DD","volume":"2","author":"Ougolkov","year":"2006","journal-title":"Targeting GSK-3: A promising approach for cancer therapy? Future Oncology"},{"key":"232","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2006-12-060947","article-title":"Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells","volume":"110","author":"Billadeau","year":"2007","journal-title":"Blood"},{"key":"233","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-06-0196","article-title":"Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: Association with kinase activity and tumor dedifferentiation","volume":"12","author":"Billadeau","year":"2006","journal-title":"Clinical Cancer Res"},{"key":"234","first-page":"507","article-title":"MicroRNA expression analysis in triple-negative (ER, PR and Her2\/neu) breast cancer","volume":"10","author":"Stathopoulos","journal-title":"Cell Cycle"},{"key":"235","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.4161\/cc.10.22.17976","article-title":"Autophagy positively regulates the CD44(+) CD24(-\/low) breast cancer stem-like phenotype","volume":"10","author":"Menendez","year":"2011","journal-title":"Cell Cycle"},{"key":"236","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI64398","article-title":"GSK-3 is a central regulator of age-related pathologies in mice","volume":"123","author":"Force","year":"2013","journal-title":"J Clin Inv"},{"key":"237","doi-asserted-by":"crossref","first-page":"16989","DOI":"10.1074\/jbc.M700610200","article-title":"Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: Functional effects in apoptosis","volume":"282","author":"Jope","year":"2007","journal-title":"J Biol Chem"},{"key":"238","doi-asserted-by":"crossref","first-page":"e15647","DOI":"10.1371\/journal.pone.0015647","article-title":"Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway","volume":"5","author":"Bi\u00e8che","year":"2010","journal-title":"PLoS One"},{"key":"239","first-page":"2892","article-title":"Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin","volume":"7","author":"McCubrey","year":"2001","journal-title":"Clin Cancer Res"},{"key":"240","first-page":"1161","article-title":"Raf-1 and Bcl-2 induce distinct and common pathways which contribute to breast cancer drug resistance","volume":"9","author":"McCubrey","year":"2003","journal-title":"Clin Cancer Res"},{"key":"241","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nm.2795","article-title":"Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance","volume":"18","author":"Pinto","year":"2012","journal-title":"Nat Med"},{"key":"242","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2007.13.7083","article-title":"Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer","volume":"27","author":"Fox","year":"2009","journal-title":"J Clin Oncol"},{"key":"243","doi-asserted-by":"crossref","first-page":"e96995","DOI":"10.1371\/journal.pone.0096995","article-title":"Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ER\u03b1 Expression in Initially ER\u03b1+ Breast Cancer Cells","volume":"9","author":"D\u2019Assoro","year":"2014","journal-title":"PLoS One"},{"key":"244","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3892\/or.2013.2313","article-title":"Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells","volume":"29","author":"D\u2019Assoro","year":"2013","journal-title":"Oncol Rep"},{"key":"245","first-page":"139","article-title":"Combining chemo-, hormonal and targeted therapies to treat breast cancer","volume":"1","author":"McCubrey","year":"2008","journal-title":"Mol Med Reports"},{"key":"246","first-page":"451","article-title":"Breast cancer: molecular basis and therapeutic strategies","volume":"1","author":"Stivala","year":"2008","journal-title":"Mol Med Reports"},{"key":"247","first-page":"139","article-title":"New innovative techniques in radiotherapy for breast cancer","volume":"68","author":"Sacchini","year":"2013","journal-title":"Minerva Chirurgica"},{"key":"248","first-page":"1","article-title":"Novel treatment options in the management of metastatic breast cancer","volume":"9","author":"Cortes","year":"2011","journal-title":"Clin Adv Hem & Oncology"},{"key":"249","doi-asserted-by":"crossref","first-page":"e53403","DOI":"10.1371\/journal.pone.0053403","article-title":"Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS ONE"},{"key":"250","doi-asserted-by":"crossref","first-page":"480","DOI":"10.18632\/aging.100472","article-title":"Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs","volume":"4","author":"Menendez","year":"2012","journal-title":"Aging"},{"key":"251","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1586\/era.11.206","article-title":"Breast cancer chemoprevention","volume":"12","author":"Jatoi","year":"2012","journal-title":"Exp Rev Anticancer Ther"},{"key":"252","first-page":"1341","article-title":"Pharmacological breast cancer therapy","volume":"27","author":"McCubrey","year":"2005","journal-title":"Int J Oncol"},{"key":"253","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Rodr\u00edguez-Lescure","year":"2013","journal-title":"Lancet Oncol"},{"key":"254","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa0910320","article-title":"Adjuvant docetaxel for high-risk, node-negative breast cancer","volume":"363","author":"Arcusa","year":"2010","journal-title":"N Engl J Med"},{"key":"255","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1586\/era.10.54","article-title":"Early recurrence risk: aromatase inhibitors versus tamoxifen","volume":"10","author":"Cognetti","year":"2010","journal-title":"Exp Rev Anticancer Ther"},{"key":"256","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.bcp.2013.08.020","article-title":"Ridaifen-SB8, a novel tamoxifen derivative, induces apoptosis via reactive oxygen species-dependent signaling pathway","volume":"86","author":"Dan","year":"2013","journal-title":"Biochem Pharmacology"},{"key":"257","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejphar.2012.11.071","article-title":"Tamoxifen resistance: From bench to bedside","volume":"717","author":"Zwart","year":"2013","journal-title":"Eur J Pharmacology"},{"key":"258","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ccr.2013.07.007","article-title":"Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer","volume":"24","author":"Sharp","year":"2013","journal-title":"Cancer Cell"},{"key":"259","doi-asserted-by":"crossref","first-page":"588","DOI":"10.18632\/oncotarget.314","article-title":"Unraveling the complexity of basal-like breast cancer","volume":"2","author":"Polyak","year":"2011","journal-title":"Oncotarget"},{"key":"260","first-page":"4242","article-title":"Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres","volume":"11","author":"Santarosa","journal-title":"Cell Cycle"},{"key":"261","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","article-title":"Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors","volume":"12","author":"Puozzo","year":"2001","journal-title":"Ann Oncol"},{"key":"262","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.12065","article-title":"Endocrine therapy: is the first generation of targeted drugs the last?","volume":"274","author":"Pritchard","year":"2013","journal-title":"J Intern Med"},{"key":"263","first-page":"5078","article-title":"HER-2-targeted therapy -Lessons learned and future directions","volume":"9","author":"Esteva1","year":"2003","journal-title":"Clin Cancer Res"},{"key":"264","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1353\/hcr.2006.0040","article-title":"The costs of caring: Who pays? Who profits? Who panders?\u201d","volume":"36","author":"Fleck","year":"2006","journal-title":"Hastings Cent Rep"},{"key":"265","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-013-0109-0","article-title":"Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"key":"266","unstructured":"K\u00fcmler, Tuxen, Nielsen. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2013. pii: S0305-7372(13)00191-6."},{"key":"267","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-13-0518","article-title":"Pertuzumab: Optimizing HER2 blockade","volume":"19","author":"Krop","year":"2013","journal-title":"Clin Cancer Res"},{"key":"268","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Kim","year":"2012","journal-title":"N Engl J Med"},{"key":"269","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1158\/1078-0432.CCR-13-1212","article-title":"First FDA approval of dual anti-HER2 regimen: Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer","volume":"19","author":"Thomas","year":"2013","journal-title":"Clin Cancer Res"},{"key":"270","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/11209000-000000000-00000","article-title":"Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer","volume":"72","author":"Keating","year":"2012","journal-title":"Drugs"},{"key":"271","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMe1211736","article-title":"The promise of antibody-drug conjugates","volume":"367","author":"Doroshow","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"272","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Blackwell","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"273","first-page":"250","article-title":"Targeted therapy for breast cancer prevention","volume":"3","author":"Brown","year":"2013","journal-title":"Front Oncol"},{"key":"274","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1038\/onc.2011.130","article-title":"Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition","volume":"30","author":"Arteaga","year":"2011","journal-title":"Oncogene"},{"key":"275","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0000000000000014","article-title":"New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer","volume":"25","author":"Andre","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"276","unstructured":"Joo, Visintin, Mor. Targeted cancer therapy - Are the days of systemic chemotherapy numbered? Maturitas. 2013. pii: S0378-5122(13)00292-2."},{"key":"277","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1185\/03007995.2013.846253","article-title":"Everolimus: a new hope for patients with breast cancer","volume":"30","author":"Altundag","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"278","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1158\/0008-5472.CAN-12-2440","article-title":"Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-Survivin axis and are sensitive to PI3K inhibitors","volume":"73","author":"Arteaga","year":"2013","journal-title":"Cancer Res"},{"key":"279","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1634\/theoncologist.2012-0129","article-title":"An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer","volume":"18","author":"Perez","year":"2013","journal-title":"Oncologist"},{"key":"280","first-page":"38","article-title":"mTOR inhibitors in the treatment of breast cancer","volume":"27","author":"Carlson","year":"2013","journal-title":"Oncology"},{"key":"281","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-013-2421-5","article-title":"Molecularly targeted therapies for metastatic triple-negative breast cancer","volume":"138","author":"Gl\u00fcck","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"282","doi-asserted-by":"crossref","first-page":"956","DOI":"10.4161\/cc.10.6.15074","article-title":"A non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifen","volume":"10","author":"Landberg","year":"2011","journal-title":"Cell Cycle"},{"key":"283","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.4161\/cc.10.10.15521","article-title":"RB pathway and therapeutic sensitivity: new insights in breast cancer and tamoxifen therapy","volume":"10","author":"Knudsen","year":"2011","journal-title":"Cell Cycle"},{"key":"284","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.4161\/cc.22543","article-title":"Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres","volume":"11","author":"Santarosa","year":"2012","journal-title":"Cell Cycle"},{"key":"285","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/jnci\/87.21.1642","article-title":"Paclitaxel in doxorubicin-resistant metastatic breast cancer patients","volume":"87","author":"Anand","year":"1995","journal-title":"J Nat Cancer Inst"},{"key":"286","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1992.10.2.304","article-title":"Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients","volume":"10","author":"DeGregorio","year":"1992","journal-title":"J Clin Oncol"},{"key":"287","doi-asserted-by":"crossref","unstructured":"McCubrey, Sokolosky, Lehmann, Taylor, Navolanic, Chappell, Abrams, Stadelman, Wong, Misaghian, B\u00e4secke, Libra, Stivala, Ligresti, Tafuri, Milella, et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an Achilles heel by sensitization to targeted therapy Adv Enzyme Regul. 2008; 48:113\u2013135.","DOI":"10.1016\/j.advenzreg.2008.02.006"},{"key":"288","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.742","article-title":"Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment","volume":"3","author":"Menendez","year":"2012","journal-title":"Oncotarget"},{"key":"289","doi-asserted-by":"crossref","first-page":"998","DOI":"10.18632\/oncotarget.632","article-title":"Phenotypic screening reveals topoisomerase I as a breast cancer stem cell therapeutic target","volume":"3","author":"Lazo","year":"2012","journal-title":"Oncotarget"},{"key":"290","first-page":"16","article-title":"Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer","volume":"3","author":"Matsuo","year":"2012","journal-title":"Oncotarget"},{"key":"291","doi-asserted-by":"crossref","first-page":"988","DOI":"10.18632\/oncotarget.634","article-title":"Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers","volume":"3","author":"Rick","year":"2012","journal-title":"Oncotarget"},{"key":"292","doi-asserted-by":"crossref","first-page":"666","DOI":"10.18632\/oncotarget.562","article-title":"Engineering enzymatically activated \u201cmolecular grenades\u201d for cancer","volume":"3","author":"Isaacs","year":"2012","journal-title":"Oncotarget"},{"key":"293","doi-asserted-by":"crossref","first-page":"869","DOI":"10.18632\/oncotarget.598","article-title":"Tumor suppression by small molecule inhibitors of translation initiation","volume":"3","author":"Halperin","year":"2012","journal-title":"Oncotarget"},{"key":"294","doi-asserted-by":"crossref","first-page":"833","DOI":"10.18632\/oncotarget.542","article-title":"Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells","volume":"3","author":"Zhang","year":"2012","journal-title":"Oncotarget"},{"key":"295","doi-asserted-by":"crossref","first-page":"608","DOI":"10.18632\/oncotarget.520","article-title":"Targeting of Rac GTPases blocks the spread of intact human breast cancer","volume":"3","author":"Harrison","year":"2012","journal-title":"Oncotarget"},{"key":"296","doi-asserted-by":"crossref","first-page":"601","DOI":"10.18632\/oncotarget.548","article-title":"Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells","volume":"3","author":"Blagosklonny","year":"2012","journal-title":"Oncotarget"},{"key":"297","doi-asserted-by":"crossref","first-page":"514","DOI":"10.18632\/oncotarget.496","article-title":"Targeting protein-tyrosine phosphatases in breast cancer","volume":"3","author":"Bentires-Alj","year":"2012","journal-title":"Oncotarget"},{"key":"298","doi-asserted-by":"crossref","first-page":"395","DOI":"10.18632\/oncotarget.488","article-title":"Metformin-induced preferential killing of breast cancer initiating CD44+CD24-\/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts","volume":"3","author":"Menendez","year":"2012","journal-title":"Oncotarget"},{"key":"299","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.18632\/oncotarget.359","article-title":"The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA","volume":"2","author":"Gartel","year":"2011","journal-title":"Oncotarget"},{"key":"300","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.18632\/oncotarget.563","article-title":"Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects","volume":"2","author":"Borden","year":"2011","journal-title":"Oncotarget"},{"key":"301","doi-asserted-by":"crossref","first-page":"810","DOI":"10.18632\/oncotarget.339","article-title":"PinX1: a sought-after major tumor suppressor at human chromosome 8p23","volume":"2","author":"Zhou","year":"2011","journal-title":"Oncotarget"},{"key":"302","doi-asserted-by":"crossref","first-page":"797","DOI":"10.18632\/oncotarget.343","article-title":"Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment","volume":"2","author":"Andre","year":"2011","journal-title":"Oncotarget"},{"key":"303","doi-asserted-by":"crossref","first-page":"654","DOI":"10.18632\/oncotarget.329","article-title":"Wiring the oncogenic circuitry: Pin1 unleashes mutant p53","volume":"2","author":"Del Sal","year":"2011","journal-title":"Oncotarget"},{"key":"304","doi-asserted-by":"crossref","first-page":"562","DOI":"10.18632\/oncotarget.301","article-title":"Targeting invadopodia to block breast cancer metastasis","volume":"2","author":"Yang","year":"2011","journal-title":"Oncotarget"},{"key":"305","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.4161\/cc.22871","article-title":"Alternatively spliced protein arginine methyltransferase 1 isoform PRMT1v2 promotes the survival and invasiveness of breast cancer cells","volume":"11","author":"Cote","year":"2012","journal-title":"Cell Cycle"},{"key":"306","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.21195","article-title":"Therapeutic response to CDK4\/6 inhibition in breast cancer defined by ex vivo analyses of human tumors","volume":"11","author":"Knudsen","year":"2012","journal-title":"Cell Cycle"},{"key":"307","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.4161\/cc.20624","article-title":"Identification of novel metastasis suppressor signaling pathways for breast cancer","volume":"11","author":"Rosner","year":"2012","journal-title":"Cell Cycle"},{"key":"308","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.4161\/cc.20598","article-title":"MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF","volume":"11","author":"Wardle","year":"2012","journal-title":"Cell Cycle"},{"key":"309","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.4161\/cc.20546","article-title":"Phospho-specific Smad3 signaling: impact on breast oncogenesis","volume":"11","author":"Jeruss","year":"2012","journal-title":"Cell Cycle"},{"key":"310","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4161\/cc.11.4.19358","article-title":"Emerging targets for the prevention of pregnancy-associated breast cancer","volume":"11","author":"Schedin","year":"2012","journal-title":"Cell Cycle"},{"key":"311","first-page":"187","article-title":"Breast cancer go sMAD: cyclin towards aggressive phenotypes","volume":"10","author":"Diehl","year":"2011","journal-title":"Cell Cycle"},{"key":"312","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4161\/cc.10.2.14479","article-title":"Inhibition of Smad3 activity by cyclin D-CDK4 and cyclin E-CDK2 in breast cancer cells","volume":"10","author":"Liu","year":"2011","journal-title":"Cell Cycle"},{"key":"313","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.4161\/cc.10.17.16359","article-title":"Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2\/IGF-1 receptor interactions","volume":"10","author":"Thor","year":"2011","journal-title":"Cell Cycle"},{"key":"314","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4161\/cc.10.7.15210","article-title":"Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF-induced oncomiR miRNA-181a","volume":"10","author":"Menendez","year":"2011","journal-title":"Cell Cycle"},{"key":"315","first-page":"2782","article-title":"Metformin is synthetically lethal with glucose withdrawal in cancer cells","volume":"11","author":"Vazquez-Martin","year":"2011","journal-title":"Cell Cycle"},{"key":"316","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4161\/cc.11.5.19252","article-title":"Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation","volume":"11","author":"Menendez","year":"2012","journal-title":"Cell Cycle"},{"key":"317","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.4161\/cc.10.23.18151","article-title":"Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue","volume":"10","author":"Sotgia","year":"2011","journal-title":"Cell Cycle"},{"key":"318","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4161\/cc.11.2.18813","article-title":"Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers","volume":"11","author":"Thor","year":"2012","journal-title":"Cell Cycle"},{"key":"319","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/cc.10.5.14956","article-title":"Stat1 is a suppressor of ErbB2\/Neu-mediated cellular transformation and mouse mammary gland tumor formation","volume":"10","author":"Koromilas","year":"2011","journal-title":"Cell Cycle"},{"key":"320","first-page":"43","article-title":"ATP binding cassette transporters and drug resistance in breast cancer","volume":"10","author":"Clarke","year":"2003","journal-title":"Endo-Rel Cancer"},{"key":"321","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.4161\/cc.22382","article-title":"Erlotinib antagonizes ABC transporters in acute myeloid leukemia","volume":"11","author":"Kroemer","year":"2012","journal-title":"Cell Cycle"},{"key":"322","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.4161\/cc.21127","article-title":"CDK4\/6 inhibition antagonizes the cytotoxic response to anthracycline therapy","volume":"11","author":"Knudsen","year":"2012","journal-title":"Cell Cycle"},{"key":"323","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.4161\/cc.22376","article-title":"Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"324","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.4161\/cc.22137","article-title":"Ketone body utilization drives tumor growth and metastasis","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"325","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.4161\/cc.22136","article-title":"Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells","volume":"11","author":"Sotgia","year":"2012","journal-title":"Cell Cycle"},{"key":"326","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.4161\/cc.19841","article-title":"Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the \u201creverse Warburg effect\u201d in positive lymph node tissue","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"327","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.4161\/cc.20920","article-title":"Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"328","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.4161\/cc.11.6.19530","article-title":"Using the \u201creverse Warburg effect\u201d to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers","volume":"11","author":"Lisanti","year":"2012","journal-title":"Cell Cycle"},{"key":"329","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.4161\/cc.10.23.18287","article-title":"The mitochondrial protein C1qbp promotes cell proliferation, migration and resistance to cell death","volume":"10","author":"Baines","year":"2011","journal-title":"Cell Cycle"},{"key":"330","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1349-7006.2011.02183.x","article-title":"Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy","volume":"103","author":"Claerhout","year":"2012","journal-title":"Cancer Sci"},{"key":"331","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4161\/cc.22026","article-title":"Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment","volume":"11","author":"Bartek","year":"2012","journal-title":"Cell Cycle"},{"key":"332","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4161\/cc.10.14.15917","article-title":"Bid as a potential target of apoptotic effects exerted by low doses of PPAR and RXR ligands in breast cancer cells","volume":"10","author":"Ando","year":"2011","journal-title":"Cell Cycle"},{"key":"333","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10549-010-0924-x","article-title":"The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells","volume":"126","author":"Menendez","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"334","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.4161\/cc.22225","article-title":"Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)","volume":"11","author":"Menendez","year":"2012","journal-title":"Cell Cycle"},{"key":"335","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.4161\/cc.21395","article-title":"Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer","volume":"11","author":"Wicha","year":"2012","journal-title":"Cell Cycle"},{"key":"336","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4161\/cc.23274","article-title":"Basal\/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)","volume":"12","author":"Menendez","year":"2013","journal-title":"Cell Cycle"},{"key":"337","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.530","article-title":"Improved clinical and cell cycle response with an mTOR inhibitor, daily oral RAD001 (everolimus) plus letrozole versus placebo plus letrozole in a randomized phase II neoadjuvant trial in ER+ breast cancer","volume":"26","author":"Baselga","year":"2008","journal-title":"J Clin Oncol"},{"key":"338","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.1057","article-title":"Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab","volume":"26","author":"Jerusalem","year":"2008","journal-title":"J Clin Oncol"},{"key":"339","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2007.14.1127","article-title":"Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data","volume":"26","author":"Lane","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"340","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","article-title":"Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer","volume":"125","author":"Gianni","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"341","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":", Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer","volume":"366","author":"Huober","year":"2012","journal-title":"N Engl J Med"},{"key":"342","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":", Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial","volume":"13","author":"Huober","year":"2012","journal-title":"Lancet Oncol"},{"key":"343","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.27790","article-title":"Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma","volume":"119","author":"Kim","year":"2013","journal-title":"Cancer"},{"key":"344","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","article-title":"Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy","volume":"29","author":"Esteva","year":"2011","journal-title":"J Clin Oncol"},{"key":"345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10549-013-2810-9","article-title":"A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure","volume":"143","author":"Elledge","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"346","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JCO.2011.38.3331","article-title":"Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer","volume":"31","author":"Hayes","year":"2013","journal-title":"J Clin Oncol"},{"key":"347","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/cncr.27790","article-title":"Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma","volume":"119","author":"Kim","year":"2013","journal-title":"Cancer"},{"key":"348","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2407-14-170","article-title":"Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)","volume":"14","author":"Jeong","year":"2014","journal-title":"BMC Cancer"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:36:36Z","timestamp":1691973396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,12]]},"references-count":348,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,7,15]]}},"alternative-id":["2209","25051360"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2209","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,12]]}}}